産婦人科領域におけるbalofloxacinの基礎的・臨床的検討  [in Japanese] Basic and clinical studies of balofloxacin in obstetrics and gynecology  [in Japanese]

Access this Article

Search this Article

Author(s)

Abstract

新規フルオロキノロン系経口用抗菌薬, balofloxacinの内性器組織内移行および産婦人科領域感染症に対する臨床効果について検討した。<BR>本剤200mg単回投与時の内性器組織内濃度は投与7.3~18.3時間後に子宮動脈血中濃度の約1.5倍に達し, 組織内移行性は良好であった。<BR>産婦人科領域感染症12例に対して1日量200mgまたは400mg (分2) を5~7日間投与した結果, 10例で有効と評価される症状の改善がみられた。細菌学的効果は4例において検討され, 分離6菌株の全てが除菌された。<BR>本剤に起因すると考えられる副作用および臨床検査値の異常変動は認められなかった。

A new oral fluoroquinolone, balofloxacin (BLFX), was evaluated for its penetration to genital tissues and its clinical effect against gynecological infections.<BR>Approximately 1.5-fold higher concentrations of the drug were found in the genital tissues than in uterine arterial serum 7.3-18.3 h after the oral administration of 200 mg, suggesting its good tissue penetration.<BR>Eleven patients with gynecological infections were treated with 200 mg or 400 mg (b.i.d.) for 5-7 days, and the overall clinical efficacy rate was 81.8%. The bacteriological effect was evaluated in 4 patients with 6 strains of isolates, and 100% eradication was achieved. No adverse reactions nor abnormal chenges in clinical findings were recognized as a result of the treatment.

Journal

  • Japanese Journal of Chemotherapy

    Japanese Journal of Chemotherapy 43, 406-412, 1995-11-27

    Japanese Society of Chemotherapy

References:  10

Codes

Page Top